Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk...

Area of Science:

• Cardiology
• Genetics
• Clinical Prediction Modeling

Background:

• Catecholaminergic polymorphic ventricular tachycardia (CPVT) poses a risk of life-threatening arrhythmic events (AEs) despite beta-blocker therapy.
• RYR2-mediated CPVT is a common genetic form requiring precise risk stratification.

Purpose of the Study:

• To develop and validate individualized risk prediction models for AEs in RYR2-mediated CPVT patients on beta-blocker monotherapy.
• To identify clinical parameters that predict future AEs in this patient population.

Main Methods:

• Development and validation of Cox regression models using data from 743 (derivation) and 129 (validation) CPVT patients.
• AEs included arrhythmic syncope, ICD shock, sudden cardiac arrest (SCA), and sudden cardiac death; near-fatal/fatal AEs (nf/fAEs) excluded syncope.
• Internal and external validation of prediction models.

Main Results:

• 13.7% and 18.6% of patients experienced AEs in derivation and validation cohorts, respectively.
• Predictors for AEs included prior arrhythmic syncope/SCA and age at beta-blocker initiation. C-indices were 0.67 (derivation) and 0.59 (validation).
• For nf/fAEs, ventricular arrhythmia severity before treatment was an additional predictor. C-indices were 0.74 (derivation) and 0.60 (validation).

Conclusions:

• Externally validated risk models accurately stratify CPVT patients on beta-blockers into low and high risk for future AEs.
• These models can guide clinical management strategies to prevent AEs in CPVT patients.